Literature DB >> 24057240

Angiogenic and anti-angiogenic factor gene transcript level quantitation by quantitative real time PCR in patients with hepatocellular carcinoma.

Bal Krishan Sharma1, Radhika Srinivasan, Shweta Kapil, Bhupesh Singla, Yogesh Kumar Chawla, Anuradha Chakraborti, Nitin Saini, Ajay Duseja, Ashim Das, Naveen Kalra, Radha Krishan Dhiman.   

Abstract

Tumor angiogenesis, a major requirement for tumor growth and metastasis, is regulated by pro- and anti-angiogenic factors. The aim of this study was to quantify the expression of angiogenic (VEGF, HIF-1α, Angiopiotein-2) and anti-angiogenic (endostatin, angiostatin and Thrombospondin-1) factors and to discern their clinical relevance. A total 90 patients (67 HCC, 9 cirrhosis and 14 chronic hepatitis) were enrolled in the study. Tissue transcript levels of angiogenic (VEGF, HIF-1α, Ang-2) and anti-angiogenic (endostatin, angiostatin and TSP-1) factors were analyzed by quantitative real time-polymerase chain reaction (qRT-PCR) in the tissue samples. The tissue transcript levels of VEGF, HIF-1α and endostatin were found to be significantly higher in HCC in comparison to cirrhosis and chronic hepatitis. Although Ang-2, angiostatin and TSP-1 tissue transcript levels were higher in HCC group than the others groups but the difference was not statistically significant. In univariate analysis both VEGF and HIF-1α were found to be associated with poor survival of HCC patients. Multivariate analysis by the cox proportional hazard model revealed only VEGF as an independent factor predicting poor survival of the HCC patients. Angiogenic and anti-angiogenic factors are all highly expressed in HCC patients. Upregulation of tissue anti-angiogenic factors indicates the urgency for the alternative of anti-angiogenic therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057240     DOI: 10.1007/s11033-013-2690-4

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  46 in total

1.  Expression of angiopoietins and its clinical significance in non-small cell lung cancer.

Authors:  Fumihiro Tanaka; Shinya Ishikawa; Kazuhiro Yanagihara; Ryo Miyahara; Yozo Kawano; Mio Li; Yosuke Otake; Hiromi Wada
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

2.  Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.

Authors:  Hiroshi Wada; Hiroaki Nagano; Hirofumi Yamamoto; Yubo Yang; Motoi Kondo; Hideo Ota; Masato Nakamura; Shinichi Yoshioka; Hitoshi Kato; Bazarragchaa Damdinsuren; Di Tang; Sigeru Marubashi; Atsushi Miyamoto; Yutaka Takeda; Koji Umeshita; Shoji Nakamori; Masato Sakon; Keizo Dono; Kenichi Wakasa; Morito Monden
Journal:  Liver Int       Date:  2006-05       Impact factor: 5.828

3.  Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

Authors:  Christian Sfiligoi; Annarita de Luca; Ilaria Cascone; Valentina Sorbello; Luca Fuso; Riccardo Ponzone; Nicoletta Biglia; Enrica Audero; Riccardo Arisio; Federico Bussolino; Piero Sismondi; Michele De Bortoli
Journal:  Int J Cancer       Date:  2003-02-10       Impact factor: 7.396

Review 4.  Regulation of angiogenesis by hypoxia-inducible factor 1.

Authors:  Kiichi Hirota; Gregg L Semenza
Journal:  Crit Rev Oncol Hematol       Date:  2006-05-22       Impact factor: 6.312

5.  Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.

Authors:  B J Lannutti; S T Gately; M E Quevedo; G A Soff; A S Paller
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

6.  Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression.

Authors:  J E Nör; J Christensen; D J Mooney; P J Polverini
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

7.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

8.  Angiostatin induces and sustains dormancy of human primary tumors in mice.

Authors:  M S O'Reilly; L Holmgren; C Chen; J Folkman
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

Review 9.  Systemic therapy of hepatocellular carcinoma: are we making progress?

Authors:  Patricia Roxburgh; T R Jeffry Evans
Journal:  Adv Ther       Date:  2008-11       Impact factor: 3.845

10.  Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery.

Authors:  Chen-Xin Dai; Qiang Gao; Shuang-Jian Qiu; Min-Jie Ju; Ming-Yan Cai; Yong-Feng Xu; Jian Zhou; Bo-Heng Zhang; Jia Fan
Journal:  BMC Cancer       Date:  2009-12-01       Impact factor: 4.430

View more
  4 in total

Review 1.  RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Authors:  Kurt Sartorius; Samuel O Antwi; Anil Chuturgoon; Lewis R Roberts; Anna Kramvis
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Inhibitory effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma.

Authors:  Qing Ye; Shukui Qin; Yanhong Liu; Jundong Feng; Qiong Wu; Wenshu Qu; Xiaojin Yin
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

3.  Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.

Authors:  Shengjie Sun; Huiyu Dong; Tao Yan; Junchen Li; Bianjiang Liu; Pengfei Shao; Jie Li; Chao Liang
Journal:  BMC Med Genet       Date:  2020-06-29       Impact factor: 2.103

4.  Oxidative stress, immunological and cellular hypoxia biomarkers in hepatitis C treatment-naïve and cirrhotic patients.

Authors:  Abdulrahman Hamdan Almaeen; Abdulrahman Abdulwahab Alduraywish; Maysa Ahmed Mobasher; Omar I M Almadhi; Hanan M Nafeh; Tarek Hassan El-Metwally
Journal:  Arch Med Sci       Date:  2020-01-03       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.